In New Zealand, prescription of GnRHa for gender dysphoria started around 2011; prevalence of use increased to 2014, then more steeply to 2022, followed by a decline. Incidence data show the decline started from 2021. New Zealand, compared to the Netherlands (which started prescribing in the 1990s), had 1.7 times the cumulative incidence of first prescriptions by 2018. Compared to England and Wales up to 2020, New Zealand had 3.5–6.9 times the cumulative incidence.
An odd assemblage of papers that could expose Aotearoa to a radical and potentially harmful experiment. That's how one public health expert describes the five documents that make up minister Casey Costello's so called independent advice on heated tobacco products....
The New Zealand College of Public Health Medicine (NZCPHM) is deeply concerned at the prospect of cuts to the National Public Health Service (NPHS). Read...
The former director-general of health Sir Ashley Bloomfield wants the government to treat pandemics as a security threat, rather than just a health one. Read...
HEALTH SERVICES AND SYSTEMS
EQUITY
Exploring the impacts of the health system on minorities within the population, notably including Māori, Pacifica, Asians and LGBTQI.
DRUGS, DEVICE AND DIAGNOSTICS
PUBLIC HEALTH
DIGITAL HEALTH
TE TIRITI